Anzeige
Mehr »
Login
Freitag, 18.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
5 Millionen Unzen und steigend: NexGold Mining's unerschlossene Goldstraße
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
1.156 Leser
Artikel bewerten:
(2)

Startup Genome: Global Startup Ecosystem Report 2024 Showcases Surging Investment in Generative AI

Global rankings and trends from the world's most comprehensive, quality-controlled dataset

SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2024 / The 2024 Global Startup Ecosystem Report (GSER) by Startup Genome and the Global Entrepreneurship Network launched today at London Tech Week, in collaboration with the Founders Forum, Informa Tech and London & Partners. The GSER analyzes data from over 4.5 million companies across 300+ entrepreneurial innovation ecosystems and features rankings that indicate which ecosystems are currently driving innovation and deep knowledge about startup trends around the world.

Compelling new insights include the notable decline in global VC funding, the sharp decrease in Exit Values, the scarcity of IPOs, the resilience of Cleantech investments, and the surge in Generative AI funding. The report also offers insights into the evolving dynamics of Series A funding, with a potential modest recovery in early-stage investment observed in Q1 2024.

Global key findings from the GSER2024 include:

  • Series A funding amount in 2023 was down 46% from 2022, and the value of large exits ($50M+) fell 47% over the same period.
  • Q1 2024 has projected higher Series A funding amount and deal count than Q4 2023.
  • The number of new unicorns in 2023 was down 58% from 2022 and 87% from the 2021 peak. With 15 unicorns, Silicon Valley led all ecosystems for the most new unicorns in 2023, though this was down 80% from 2022.
  • In 2023, more than half of new unicorns were in the GenAI and Deep Tech sub-sectors, a higher rate than 2021.
  • Late-stage Cleantech startups raised 2.5x more funding in H2 2023 than in H1 2020. Europe has outperformed the U.S. and China in terms of Cleantech Series A funding growth from 2021 to 2023.
  • Generative AI saw a surge in funding, with nearly 20% of all VC funding in 2023 going to GenAI-focused startups. GenAI VC funding increased 3x in 2023 compared to 2022. Deal counts nearly doubled.
  • In 2023, the Series A funding amount share for Top 40 ranked GSER 2024 ecosystems was 65%, down from 79% for these ecosystems in 2019. The share of Series A funding amount for the Top 100 Emerging Ecosystems reached 19% in 2023 vs. 13% in 2019.
  • Top three global ecosystems: Silicon Valley remains at the top, followed by New York City and London tied for #2.
  • Europe is the most represented region in the Emerging Ecosystems Ranking, with a 42% share in the Top 100 Emerging Ecosystems, followed by North America with 27%.

"We persist in our role as expert advisors, dedicated to accelerating entrepreneurship and growth in startup ecosystems and innovation clusters worldwide. The Global Startup Ecosystem Report, as the most comprehensive and data-driven analysis in this domain, serves as the foundation of our mission," emphasizes Stephan Kuester, Managing Partner at Startup Genome. "Armed with the right knowledge, we work side by side with entrepreneurs, policymakers, and community leaders globally in demonstrating how innovative technologies can drive exponential economic growth."

The 2024 edition ranks the Top 40 global ecosystems, a ranking of emerging ecosystems, and expanded regional rankings. The report, driven by a consortium of representatives from 40+ countries, looks at the current state of startup activity and related investment. It also highlights startup communities from a regional perspective, separately ranking ecosystems in Asia, Europe, Latin America, MENA, North America, Oceania, and sub-Saharan Africa. Contributions from thought leaders further enrich the report's extensive evidence-based findings, which are the product of over a decade of Startup Genome's independent research and policy work.

"Creating more entrepreneurs is the most important thing that we can do as an ecosystem of enablers and policymakers. […] The progress we make on these issues in the next decade will determine the success of the next 100 years and beyond," shares Jonathan Ortmans, President of the Global Entrepreneurship Network.

The GSER is created in partnership with the Global Entrepreneurship Network, Dealroom, Crunchbase, and Bella Private Markets. The 2024 edition provides guidance to public and private leaders on how to foster thriving startup communities - the #1 engine of job creation and economic growth. Discover how 140 entrepreneurial ecosystems across the world stack up and view the full report here: https://startupgenome.com/gser2024.

Contact Information

Franzis Walther
Manager, Operations & Communications, Startup Genome
franzis@startupgenome.com

SOURCE: Startup Genome

.

View the original press release on newswire.com.

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.